Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ventyx Biosciences Inc (VTYX)

Ventyx Biosciences Inc (VTYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 156,178
  • Shares Outstanding, K 70,669
  • Annual Sales, $ 0 K
  • Annual Income, $ -192,960 K
  • EBIT $ -186 M
  • EBITDA $ -185 M
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 76.81% ( -14.80%)
  • Historical Volatility 66.12%
  • IV Percentile 19%
  • IV Rank 11.49%
  • IV High 457.20% on 02/07/24
  • IV Low 27.41% on 08/08/24
  • Put/Call Vol Ratio 0.55
  • Today's Volume 118
  • Volume Avg (30-Day) 283
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 5,903
  • Open Int (30-Day) 5,705

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.48
  • Number of Estimates 5
  • High Estimate -0.43
  • Low Estimate -0.52
  • Prior Year -0.92
  • Growth Rate Est. (year over year) +47.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.03 +6.40%
on 10/10/24
2.60 -16.92%
on 10/17/24
-0.02 (-0.92%)
since 09/30/24
3-Month
1.79 +20.67%
on 08/22/24
2.78 -22.30%
on 09/23/24
-0.14 (-6.09%)
since 07/30/24
52-Week
1.79 +20.67%
on 08/22/24
15.81 -86.33%
on 11/03/23
-12.22 (-84.98%)
since 10/30/23

Most Recent Stories

More News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

VTYX : 2.16 (-2.26%)
Why Shares of Ventyx Biosciences Are Dropping Tuesday

Investors were unimpressed by the company's trial results for an ulcerative colitis therapy.

PFE : 28.30 (-0.77%)
VTYX : 2.16 (-2.26%)
Why Shares of Ventyx Biosciences Rose Monday

The company has several promising autoimmune therapies.

DICE : 47.55 (+0.06%)
RXDX : 199.92 (+0.09%)
MRK : 102.32 (-2.39%)
LLY : 829.74 (-2.02%)
VTYX : 2.16 (-2.26%)
Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week

The biotech benefits from a much larger peer's recent FDA approval.

VTYX : 2.16 (-2.26%)
Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2...

VTYX : 2.16 (-2.26%)
Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company...

VTYX : 2.16 (-2.26%)
Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our selective NLRP3 inhibitor, VTX2735,...

VTYX : 2.16 (-2.26%)
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company...

VTYX : 2.16 (-2.26%)
Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor,...

VTYX : 2.16 (-2.26%)
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage...

VTYX : 2.16 (-2.26%)

Business Summary

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in...

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.26
1st Resistance Point 2.21
Last Price 2.16
1st Support Level 2.13
2nd Support Level 2.09
3rd Support Level 2.04

See More

52-Week High 15.81
Fibonacci 61.8% 10.45
Fibonacci 50% 8.80
Fibonacci 38.2% 7.14
Last Price 2.16
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar